Mangoceuticals, a pharmaceutical company, has reported a series of financial and business developments in its recent announcement. Financial Performance details were not provided, hence cannot be summarized. In terms of Business Development, the company has entered into an employment agreement with Mrs. Amanda Hammer as Chief Operating Officer, effective May 1, 2023. Her compensation package includes a base salary of $150,000, a sign-on bonus comprising 75,000 shares of common stock, and options for an additional 150,000 shares. The company has also engaged in various agreements and transactions with related parties, including a Master Services Agreement with Epiq Scripts, LLC, which is partially owned by Mangoceuticals' CEO, Jacob D. Cohen. Additionally, the company has issued stock options and shares to various executives and directors, including...Show More

Mangoceuticals, a pharmaceutical company, has reported a series of financial and business developments in its recent announcement. Financial Performance details were not provided, hence cannot be summarized. In terms of Business Development, the company has entered into an employment agreement with Mrs. Amanda Hammer as Chief Operating Officer, effective May 1, 2023. Her compensation package includes a base salary of $150,000, a sign-on bonus comprising 75,000 shares of common stock, and options for an additional 150,000 shares. The company has also engaged in various agreements and transactions with related parties, including a Master Services Agreement with Epiq Scripts, LLC, which is partially owned by Mangoceuticals' CEO, Jacob D. Cohen. Additionally, the company has issued stock options and shares to various executives and directors, including a grant of stock options to Mr. Cohen. Future Plans were not explicitly mentioned in the announcement. The company's board has determined that several directors are independent under Nasdaq rules, and all services provided by the independent registered public accounting firm, Turner, Stone & Company, L.L.P., were pre-approved by the board for the year ended December 31, 2023.